Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cassava Sciences Inc (SAVA)

Cassava Sciences Inc (SAVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs

Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.

BIIB : 231.99 (-0.78%)
RHHBY : 49.8450 (-0.37%)
LLY : 249.37 (+0.93%)
SAVA : 40.46 (-2.46%)
Where Will Cassava Sciences Be in 1 Year?

It could be a make-or-break year for the clinical-stage biotech.

SAVA : 40.46 (-2.46%)
Global Alzheimer’s Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028

Palm Beach, FL –January 4, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory...

HOTH : 0.7551 (+4.08%)
ABBV : 136.33 (-0.33%)
SNY : 52.01 (-0.31%)
REGN : 621.05 (+1.61%)
SAVA : 40.46 (-2.46%)
Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

SAVA : 40.46 (-2.46%)
Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease

New website (www.Rethink-ALZ.com) is intended to increase visibility and information for potential study participants.Rethink-ALZ.com connects patients...

SAVA : 40.46 (-2.46%)
Biogen (BIIB) to Cut Alzheimer's Drug Aduhelm Price by 50%

Biogen (BIIB) said it is lowering the wholesale acquisition cost (WAC) of Aduhelm by approximately 50%, effective Jan 1, 2022

BIIB : 231.99 (-0.78%)
RHHBY : 49.8450 (-0.37%)
LLY : 249.37 (+0.93%)
SAVA : 40.46 (-2.46%)
Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Publication

Editor-in-Chief States: “After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the Western Blot...

SAVA : 40.46 (-2.46%)
Is Cassava Sciences a Good Biotech Stock to Invest In?

Biotech company Cassava Sciences (SAVA) is known for its Alzheimer’s drug, currently in phase three clinical trials. The stock has gained triple digits so far this year. However, with the SEC investigating...

SAVA : 40.46 (-2.46%)
SBHMY : 14.5800 (-0.07%)
OTSKY : 17.9200 (-0.11%)
VRTX : 231.33 (+0.11%)
CORRECTING and REPLACING CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Second paragraph of release dated December 3, 2021, should read: The lawsuit alleges that... (instead of The complaint, filed on January 5, 2021, alleges that...)

SAVA : 40.46 (-2.46%)
CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (NASDAQ: SAVA) on behalf of long-term stockholders following...

SAVA : 40.46 (-2.46%)

Barchart Exclusives

Will Platinum Finally Rally In 2022?
Platinum’s price action has lagged behind the gold, silver, and palladium markets over the past years. Laggards often become leaders, but in early 2022, platinum remains a precious metal that has lost its shine for investors. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar